Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Conditions

Squamous Cell Carcinoma of Head and Neck 12Oropharyngeal Neoplasms 12Lung Neoplasms 9Carcinoma 8Mouth Neoplasms 7Laryngeal Neoplasms 7Mesothelioma, Malignant 6Hypopharyngeal Neoplasms 6Carcinoma, Non-Small-Cell Lung 6Uterine Cervical Neoplasms 5Nasopharyngeal Carcinoma 5Urinary Bladder Neoplasms 4Pancreatic Neoplasms 4Triple Negative Breast Neoplasms 3Salivary Gland Neoplasms 3Lymphoid Interstitial Pneumonia 3Gallbladder Neoplasms 3Testicular Neoplasms 2Seminoma 2Medulloblastoma 2Ganglioneuroblastoma 2Cholangiocarcinoma 2Carcinoma, Transitional Cell 2Breast Neoplasms 2Adenocarcinoma of Lung 2Wilms Tumor 1Vulvar Neoplasms 1Vaginal Neoplasms 1Tongue Neoplasms 1Teratoma 1

Interventions

Taxes 2Paclitaxel 2Immunoglobulin G 2Disulfides 2Carboplatin 2Bevacizumab 2adavosertib 1Platinum 1Metformin 1Gemcitabine 1Drug Therapy 1Cisplatin 11,2-diaminocyclohexaneplatinum II citrate 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Brenner Tumor × Platinum × 90 days × Clear all
NCT00951496 2026-06-02

Bevacizumab and Intravenous or Intraperitoneal Chemotherapy in Treating Patients With Stage II-III Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer

National Cancer Institute (NCI)

Phase 3 Completed
1,560 enrolled 19 charts

Brenner Tumor

Data powered by HemOnc (CC BY 4.0) Colophon âš¡